GSK3B and non-small cell lung carcinoma: Additionally, NSCLC patients with poorly differentiated tumors or in the relatively early stage subgroups (T1+T2, N0+N1 and M0) with positive GSK3β expression had significantly shorter survival times (P = 0.013, P = 0.003, P = 0.010 and P = 0.008, respectively; shown in Figure 2B-E).